1 reports of this reaction
1.1% of all GUAIFENESIN AND PSEUDOEPHEDRINE HCL reports
#5 most reported adverse reaction
ABNORMAL WEIGHT GAIN is the #5 most commonly reported adverse reaction for GUAIFENESIN AND PSEUDOEPHEDRINE HCL, manufactured by H E B. There are 1 FDA adverse event reports linking GUAIFENESIN AND PSEUDOEPHEDRINE HCL to ABNORMAL WEIGHT GAIN. This represents approximately 1.1% of all 92 adverse event reports for this drug.
Patients taking GUAIFENESIN AND PSEUDOEPHEDRINE HCL who experience abnormal weight gain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ABNORMAL WEIGHT GAIN is a less commonly reported adverse event for GUAIFENESIN AND PSEUDOEPHEDRINE HCL, but still significant enough to appear in the safety profile.
In addition to abnormal weight gain, the following adverse reactions have been reported for GUAIFENESIN AND PSEUDOEPHEDRINE HCL:
The following drugs have also been linked to abnormal weight gain in FDA adverse event reports:
ABNORMAL WEIGHT GAIN has been reported as an adverse event in 1 FDA reports for GUAIFENESIN AND PSEUDOEPHEDRINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
ABNORMAL WEIGHT GAIN accounts for approximately 1.1% of all adverse event reports for GUAIFENESIN AND PSEUDOEPHEDRINE HCL, making it a notable side effect.
If you experience abnormal weight gain while taking GUAIFENESIN AND PSEUDOEPHEDRINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.